Capital Cell continues to invest in Biomedicine

Integral service around a transaction
BY : Diego GutiérrezOctober Thu, 2020

Capital Cell is Europe's first online investment platform specialising in biomedicine. Despite the global coronavirus pandemic, it has raised 4 million euros of investment for 4 companies in the first quarter of 2020. The coronavirus crisis is hitting the global economy hard, especially in our country. 

After a tough quarter for the markets, investment funds have opted to bet on biomedical high-tech companies, a sector in full bloom in Spain. This is the case of Cell Capital. 

Biotechnology, the only sector to be spared 

According to Capital Cell CEO Daniel Oliver"In a context such as the current one, the importance of biotechnology goes from being strategic to being urgent, and it is going to establish itself as one of the most desirable investment sectors". The investment made by Capital Cell alone would represent more than 12% of the total investment made in the biotechnology sector in Spain in 2018, which amounted to €98 million according to the Spanish Association of Biotechnology Companies. 

However, it is not only Spain that is experiencing a growth in the investment in biotechnology. Between February and March, the biotech sector was the best performing investment in the US NASDAQ index, while most other investment sectors, including financials, energy and real estate, recorded historic declines. 

Capital Cell doesn't miss a beat 

Capital Cell doesn't miss a beat 

The online investment platform specialising in biomedicine invested four million euros in four companies in the biotech sector in the first quarter of this year, which is 37% more than in the same period last year. It is also more than a third of the total invested last year, as €11.6m was moved in 2019. 

For example, since the start of the Covid-19 crisis confinement, Capital Cell has successfully launched and closed a ¤560,000 investment round for Valencian digital diagnostic system companyeKuore. Also other start-ups such asAortyx,DevicareoAbility Pharma6 million have been confirmed. 

The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?